Commonwealth Equity Services
PMCB icon

Commonwealth Equity Services’s PharmaCyte Biotech PMCB Stock Holding History

Commonwealth Equity Services’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
20,255
+9,942
+96% +$7.48K ﹤0.01% 4381
2026
Q1 		$6.86K Buy
+10,313
New +$7.89K ﹤0.01% 4289

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Commonwealth Equity Services's PMCB Position: Q2 2026 in Review

Commonwealth Equity Services increased its PharmaCyte Biotech (PMCB) stake by 96% in Q2 2026, buying an estimated $7.48K and bringing the position to 20,255 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4381.

Commonwealth Equity Services first reported a position in PMCB in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Commonwealth Equity Services held 20,255 shares of PharmaCyte Biotech worth $15.6K as of Q2 2026.
  • Commonwealth Equity Services bought 9,942 PharmaCyte Biotech shares in Q2 2026, an estimated $7.48K.
  • PharmaCyte Biotech made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4381 holding.
  • Commonwealth Equity Services first reported a position in PharmaCyte Biotech in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.